DDInter336 DDInter1110
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Macimorelin
Celecoxib {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Macimorelin
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Clonidine
Clonidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Celecoxib {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Atropine
Atropine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Celecoxib {u} (Compound) causes {v} (Side Effect) Skin exfoliation
Skin exfoliation {u} (Side Effect) is caused by {v} (Compound) Pentamidine
Pentamidine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Celecoxib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Celecoxib {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Macimorelin
Celecoxib {u} (Compound) resembles {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Vemurafenib {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Propylthiouracil
Propylthiouracil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Celecoxib {u} (Compound) upregulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) is upregulated by {v} (Compound) Perphenazine
Perphenazine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Celecoxib (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clonidine (Compound) and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Celecoxib (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Atropine (Compound) and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Celecoxib (Compound) causes Skin exfoliation (Side Effect) and Skin exfoliation (Side Effect) is caused by Pentamidine (Compound) and Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Celecoxib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Macimorelin
Celecoxib (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Celecoxib (Compound) resembles Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound) and Vemurafenib may lead to a major life threatening interaction when taken with Macimorelin
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Propylthiouracil (Compound) and Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Celecoxib (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is upregulated by Perphenazine (Compound) and Perphenazine may lead to a major life threatening interaction when taken with Macimorelin